NO165229B - DEVICE FOR EMPTYING A FLEXIBLE TRANSPORT CONTAINER. - Google Patents
DEVICE FOR EMPTYING A FLEXIBLE TRANSPORT CONTAINER. Download PDFInfo
- Publication number
- NO165229B NO165229B NO850974A NO850974A NO165229B NO 165229 B NO165229 B NO 165229B NO 850974 A NO850974 A NO 850974A NO 850974 A NO850974 A NO 850974A NO 165229 B NO165229 B NO 165229B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- reacted
- acid
- product
- ethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 11
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 5
- -1 copper (I) halide Chemical class 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 3
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical class O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 150000003461 sulfonyl halides Chemical class 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 94
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 38
- 239000013078 crystal Substances 0.000 description 27
- 239000000047 product Substances 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 238000001953 recrystallisation Methods 0.000 description 12
- 239000003208 petroleum Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 9
- 229940124530 sulfonamide Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- FDYJJKHDNNVUDR-UHFFFAOYSA-N 2-ethyl-2-methylbutanedioic acid Chemical compound CCC(C)(C(O)=O)CC(O)=O FDYJJKHDNNVUDR-UHFFFAOYSA-N 0.000 description 2
- WXUAQHNMJWJLTG-UHFFFAOYSA-N 2-methylbutanedioic acid Chemical compound OC(=O)C(C)CC(O)=O WXUAQHNMJWJLTG-UHFFFAOYSA-N 0.000 description 2
- HXFIRQHMXJBTRV-UHFFFAOYSA-N 3,4-dimethyloxolane-2,5-dione Chemical compound CC1C(C)C(=O)OC1=O HXFIRQHMXJBTRV-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010034759 Petit mal epilepsy Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- WOPLHDNLGYOSPG-UHFFFAOYSA-N 2-butylbutanedioic acid Chemical compound CCCCC(C(O)=O)CC(O)=O WOPLHDNLGYOSPG-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- HRMQFEOLGGKZLJ-UHFFFAOYSA-N 3-ethyl-3-methyloxolane-2,5-dione Chemical compound CCC1(C)CC(=O)OC1=O HRMQFEOLGGKZLJ-UHFFFAOYSA-N 0.000 description 1
- DFATXMYLKPCSCX-UHFFFAOYSA-N 3-methylsuccinic anhydride Chemical compound CC1CC(=O)OC1=O DFATXMYLKPCSCX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B67—OPENING, CLOSING OR CLEANING BOTTLES, JARS OR SIMILAR CONTAINERS; LIQUID HANDLING
- B67B—APPLYING CLOSURE MEMBERS TO BOTTLES JARS, OR SIMILAR CONTAINERS; OPENING CLOSED CONTAINERS
- B67B7/00—Hand- or power-operated devices for opening closed containers
- B67B7/24—Hole-piercing devices
- B67B7/26—Hole-piercing devices combined with spouts
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B67—OPENING, CLOSING OR CLEANING BOTTLES, JARS OR SIMILAR CONTAINERS; LIQUID HANDLING
- B67D—DISPENSING, DELIVERING OR TRANSFERRING LIQUIDS, NOT OTHERWISE PROVIDED FOR
- B67D3/00—Apparatus or devices for controlling flow of liquids under gravity from storage containers for dispensing purposes
- B67D3/04—Liquid-dispensing taps or cocks adapted to seal and open tapping holes of casks, e.g. for beer
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
- Bag Frames (AREA)
Description
Analogifremgangsmåte for fremstilling av substituerte succinimider som er egnet til behandling av epilepsi. Analogous process for the preparation of substituted succinimides suitable for the treatment of epilepsy.
Denne oppfinnelse angår en fremgangsmåte for fremstilling av nye forbindelser som er egnet til behandling av epilepsi. This invention relates to a method for the production of new compounds which are suitable for the treatment of epilepsy.
Det er tidligere vist at forbindelsen a-etyl-a-metyl-succinimid er effektiv mot "Petit Mal"-formen av epilepsi, men den er langt mindre effektiv mot "Grand Mal"-formen, og dens effektive dose nærmer seg da det giftige nivå. The compound α-ethyl-α-methyl-succinimide has previously been shown to be effective against the "Petit Mal" form of epilepsy, but it is far less effective against the "Grand Mal" form, and its effective dose approaches then the toxic level.
Det er nu funnet at visse derivater av a-etyl-a-metyl-succinimid og beslektede forbindelser, som er mer presist definert i det følgende, er betraktelig mer fysiologisk tål-bare og er i besittelse av et meget gunstig forhold for anti-krampeaktivitet til uønskede bivirkninger. It has now been found that certain derivatives of α-ethyl-α-methyl-succinimide and related compounds, which are more precisely defined in the following, are considerably more physiologically tolerable and possess a very favorable ratio of anticonvulsant activity to unwanted side effects.
Forbindelsene som fremstilles ved fremgangsmåten ifølge oppfinnelsen, har den generelle formel The compounds produced by the method according to the invention have the general formula
12 3 12 3
hvor R , R og R betyr hydrogenatomer, eller like eller for-skjellige alkylgrupper med 1 til 5 karbonatomer, idet minst én where R , R and R mean hydrogen atoms, or the same or different alkyl groups with 1 to 5 carbon atoms, with at least one
12 3 12 3
og ikke mer enn to av substituentene R , R og R er forskjellig and no more than two of the substituents R, R and R are different
5 4 5 4
fra hydrogen; R betyr et hydrogen- eller halogen-atom, og R betyr et hydrogenatom, eller en lavere alkyl- eller hydroksy-lavere alkylgruppe. from hydrogen; R means a hydrogen or halogen atom, and R means a hydrogen atom, or a lower alkyl or hydroxy-lower alkyl group.
Disse nye forbindelser er i besitte'lse av særlig gode farmakologiske egenskaper, innbefattet sterk anti-krampe-aktivitet og særlig god tålbarhet, og er nyttige til behandling av epilepsi. De oppviser også diuretisk aktivitet på grunn av til-stedeværelsen av en sulfonamidogruppe. These new compounds possess particularly good pharmacological properties, including strong anti-convulsant activity and particularly good tolerability, and are useful for the treatment of epilepsy. They also exhibit diuretic activity due to the presence of a sulfonamido group.
1 2 1 2
Fortrinnsvis er substituentene R og R henholdsvis Preferably, the substituents are R and R respectively
en metyl- og en etylgruppe, og R <3.>et hydrogenatom. a methyl and an ethyl group, and R <3.> a hydrogen atom.
De nye forbindelser danner salter med baser, f.eks. alkalimetallsalter, så som natriumsalter, eller salter med ammoniakk eller aminer. The new compounds form salts with bases, e.g. alkali metal salts, such as sodium salts, or salts with ammonia or amines.
Forbindelsen N-(a-etyl-a-metyl-N-succinimido)-4-sulfonamido-benzen har vist seg å ha særlig gunstige egenskaper ved farmakologiske prøver, idet dens perorale LD^0 er i stør-relsesorden 4000 mg/ kg eller mer hos mus, sammenlignet med a-etyl-a-metyl-succinimid som har en peroral LD^q hos mus på The compound N-(α-ethyl-α-methyl-N-succinimido)-4-sulfonamido-benzene has been shown to have particularly favorable properties in pharmacological tests, as its peroral LD^0 is in the order of magnitude 4000 mg/kg or more in mice, compared to α-ethyl-α-methyl-succinimide which has an oral LD^q in mice of
ca. 1500 mg/ kg. Ved elektro-sjokkprøven som er et mål for aktivitet mot "Grand Mal" epilepsi, var dens perorale ED^0 hos mus så lav som 5 mg/ kg, mens den tilsvarende verdi hos albino- about. 1500 mg/kg. In the electroshock test, which is a measure of activity against "Grand Mal" epilepsy, its oral ED^0 in mice was as low as 5 mg/kg, while the corresponding value in albino
rotter var 25 mg/ kg. Ved de samme prøver viste a-etyl-a-metyl-succinimid en ED50 på 500 mg/ kg. Ved "Cardiazol"-sjokkprøven som er et mål for effektivitet, mot "Petit Mal"-epilepsi, ble den perorale ED,-0 for N-(a-etyl-a-metyl-succinimido)-4-sulfonamido-benzen vist å være 600 mg/ kg, sammenlignet rats was 25 mg/kg. In the same tests, α-ethyl-α-methyl-succinimide showed an ED50 of 500 mg/kg. In the "Cardiazol" shock test, which is a measure of efficacy, against "Petit Mal" epilepsy, the oral ED,-0 for N-(α-ethyl-α-methyl-succinimido)-4-sulfonamido-benzene was shown to be 600 mg/kg, compared
med 200 - 300 mg/ kg for a-etyl-a-metyl-succinimid, men det skal legges merke til at forholdet for ED50/LD^Q er betydelig bedre for den nye forbindelse som fremstilles ved fremgangsmåten ifølge oppfinnelsen. Denne forbindelse oppviste ingen bedøvende virk-ning opp til 200 mg/ kg. Andre forbindelser med formel I har tilsvarende egenskaper. with 200 - 300 mg/kg for α-ethyl-α-methyl-succinimide, but it should be noted that the ratio for ED50/LD^Q is significantly better for the new compound produced by the method according to the invention. This compound showed no anesthetic effect up to 200 mg/kg. Other compounds of formula I have similar properties.
Én eller flere av forbindelsene med formel I kan formes til farmasøytiske preparater sammen med ett eller flere farmasøytiske bæremidler eller fortynningsmidler. One or more of the compounds of formula I can be formed into pharmaceutical preparations together with one or more pharmaceutical carriers or diluents.
Således kan f.eks. preparatene være i form av tabletter, dragéer, kapsler, karameller, suppositorier, ampuller for injisering, oppløsninger osv. Thus, e.g. the preparations be in the form of tablets, dragées, capsules, caramels, suppositories, ampoules for injection, solutions, etc.
Bæremidlene eller fortynningsmidlene i slike preparater kan f.eks. være de som vanligvis anvendes for slike former, og kan omfatte stivelse, laktose, magnesium-stearat, talk, ge-latin, sterilt vann eller suspenderings-, emulgerings-, disper-gerings-, fortyknings- eller smaksmidler. The carriers or diluents in such preparations can e.g. be those usually used for such forms, and may include starch, lactose, magnesium stearate, talc, gelatin, sterile water or suspending, emulsifying, dispersing, thickening or flavoring agents.
Doseenhetsformer så som tabletter, kapsler, suppositorier og ampuller foretrekkes, og hensiktsmessig inneholder hver enhet 10 til 1000 mg aktiv bestanddel, fortrinnsvis 100 til 300 mg. Unit dosage forms such as tablets, capsules, suppositories and ampoules are preferred, and conveniently each unit contains 10 to 1000 mg of active ingredient, preferably 100 to 300 mg.
Preparatene inneholder fortrinnsvis den aktive forbindelse i en konsentrasjon på mellom 0,10 og 80,0 vekt-%. The preparations preferably contain the active compound in a concentration of between 0.10 and 80.0% by weight.
I tysk patent 1.041.047 er beskrevet substituerte succinimider med anti-epileptisk aktivitet, og det er angitt en LD50 på 5000 mg/ kg og en ED5Q på 700 mg/ kg, hvilket gir et terapeutisk forhold (LDgQ:ED^0) på 7,14. In German patent 1,041,047, substituted succinimides with anti-epileptic activity are described, and an LD50 of 5000 mg/kg and an ED5Q of 700 mg/kg are stated, which gives a therapeutic ratio (LDgQ:ED^0) of 7 ,14.
I østerrtek patent 242.132 som også angår substituerte succinimider, er prøveresultatene for to forbindelser gitt som følger: In Österrtek patent 242,132 which also relates to substituted succinimides, the test results for two compounds are given as follows:
LD,^:1900 mg/ kg, EDC^:195 mg/ kg, hvilket gir et LD,^:1900 mg/kg, EDC^:195 mg/kg, which gives a
50 DO 50 DO
terapeutisk forhold på 9,74; og LD50:2000 mg/ kg, ED5Q:47 mg/ kg, hvilket gir et terapeutisk forhold på 42,55. therapeutic ratio of 9.74; and LD50:2000 mg/kg, ED5Q:47 mg/kg, giving a therapeutic ratio of 42.55.
Produktene i henhold til de følgende eksempler 1, 5 og 6 har imidlertid LDgQ-verdier på henholdsvis 4200-5000, However, the products according to the following examples 1, 5 and 6 have LDgQ values of 4200-5000 respectively,
4800 og 5000 mg/kg og ED5Q-verdier på henholdsvis 25, lo-25 og 25-50 mg/ kg, hvilket gir terapeutiske forhold på henholdsvis 168-200, 192-480 og 100-200. 4800 and 5000 mg/kg and ED5Q values of 25, lo-25 and 25-50 mg/kg respectively, giving therapeutic ratios of 168-200, 192-480 and 100-200 respectively.
I henhold til oppfinnelsen fremstilles de nye forbindelser med formel I som ovenfor angitt, ved at According to the invention, the new compounds of formula I are prepared as indicated above, by
a) et amin med formelen a) an amine with the formula
4 5 hvor R og R er som ovenfor angitt, omsettes med en syre med formelen 4 5 where R and R are as indicated above, is reacted with an acid with the formula
12 3 12 3
hvor R , R og R er som ovenfor angitt, eller med et reaktivt derivat derav, for å danne det ønskede succinimido-derivat, eller where R , R and R are as above, or with a reactive derivative thereof, to form the desired succinimido derivative, or
b) et amin med formelen b) an amine of the formula
hvor R 5 er som ovenfor angitt, omsettes med en syre med formel (III) angitt ovenfor eller et reaktivt derivat derav, og for å innføre en sulfonamidogruppe i det således dannede produkt, where R 5 is as indicated above, is reacted with an acid of formula (III) indicated above or a reactive derivative thereof, and to introduce a sulfonamido group into the thus formed product,
omsettes produktet derefter med et sulfonylhalogenid, og den erholdte forbindelse omsettes med ammoniakk eller et amin med the product is then reacted with a sulfonyl halide, and the resulting compound is reacted with ammonia or an amine with
4 4 4 4
formelen I^NR , hvor R er som ovenfor angitt, eller the formula I^NR , where R is as indicated above, or
c) et amin med formelen c) an amine of the formula
5 5
hvor R er som ovenfor angitt, omsettes med en syre med formel (III) som angitt ovenfor eller et.reaktivt derivat derav, og for å innføre en sulfonamidogruppe i det således dannede produkt reduseres nitrogruppen til en aminogruppe, og derefter diazoteres produktet og omsettes med svoveldioksyd og et kob-ber (I) halogenid, og den erholdte forbindelse inneholdende en where R is as stated above, is reacted with an acid of formula (III) as stated above or a reactive derivative thereof, and to introduce a sulfonamido group into the product thus formed, the nitro group is reduced to an amino group, and then the product is diazotized and reacted with sulfur dioxide and a copper (I) halide, and the compound obtained containing a
halogensulfonylgruppe omsettes med ammoniakk eller et amin med halosulfonyl group is reacted with ammonia or an amine with
4 4 4 4
formelen f^NR / hvor R er som ovenfor angitt, the formula f^NR / where R is as stated above,
idet omsetningen med syren med formel (III) kan utføres i et enkelt trinn eller i to trinn. in that the reaction with the acid of formula (III) can be carried out in a single step or in two steps.
Når reaksjonen med syren utføres i to trinn, vil det første produkt være et hemisuccinylderivat og kan eventuelt iso-leres før endelig ringslutning. vanligvis krever den endelige kondensasjon en reaksjonstemperatur av størrelsesorden 200°C, When the reaction with the acid is carried out in two steps, the first product will be a hemisuccinyl derivative and can optionally be isolated before final ring closure. usually the final condensation requires a reaction temperature of the order of 200°C,
og for enkelttrinnsreaksjoner bør reaksjonen utføres ved en temperatur av denne størrelsesorden. Halv-kondensasjonen av rav-syren med formel III finner vanligvis sted i området 80 - 100°C. and for single-step reactions, the reaction should be carried out at a temperature of this order of magnitude. The half-condensation of the succinic acid of formula III usually takes place in the range 80 - 100°C.
Den første kondensasjon for å danne hemisuccinyl-derivatet utføres likeledes ved enkel oppvarming i et inert oppløsningsmiddel, f.eks. et hydrokarbon, nitrohydrokarbon, klor-hydrokarbon, eter eller cyklisk eter. Det annet trinn for å fujribringe ringslutning kan f.eks. utføres i nærvær av et dehydra-tiseringsmiddel så som et vannfritt salt, f.eks. natriumacetat eller svovelsyre, fosforsyre eller polyfosfor-syre eller fosfor-pentoksyd eller ganske enkelt ved oppvarming til ca. 200°C i fravær av oppløsningsmiddel med eller uten vakuum. The first condensation to form the hemisuccinyl derivative is likewise carried out by simple heating in an inert solvent, e.g. a hydrocarbon, nitrohydrocarbon, chlorohydrocarbon, ether or cyclic ether. The second step for generating circularity can e.g. is carried out in the presence of a dehydrating agent such as an anhydrous salt, e.g. sodium acetate or sulfuric acid, phosphoric acid or polyphosphoric acid or phosphorous pentoxide or simply by heating to approx. 200°C in the absence of solvent with or without vacuum.
Reaksjonstiden for reaksjonen med den frie syre er fortrinnsvis 1-5 timer, hensiktsmessig ca. 2 timer. Efctrinns-reaksjonen med anhydridet utføres fortrinnsvis ved ca. 200°C The reaction time for the reaction with the free acid is preferably 1-5 hours, suitably approx. 2 hours. The effect step reaction with the anhydride is preferably carried out at approx. 200°C
i kort tid. in a short time.
De følgende eksempler skal tjene til å illustrere oppfinnelsen ytterligere. The following examples shall serve to further illustrate the invention.
Eksempel 1 Example 1
1- N-( a- etyl- g- metyl- succinimido)- 4- sulfonamido- benzen 17,2 g sulfanilamid (1 mol) oppvarmes i 30 minutter ved 1- N-(a- ethyl- g- methyl- succinimido)- 4- sulfonamido- benzene 17.2 g of sulfanilamide (1 mol) are heated for 30 minutes at
160°C med 160°C incl
16,0 g a-etyl-a-metyl-ravsyre (1 mol). 16.0 g α-ethyl-α-methyl-succinic acid (1 mol).
Den resulterende olje oppløses i etylacetat, avkjøles The resulting oil is dissolved in ethyl acetate, cooled
og filtreres med sugning for å gi and filtered with suction to give
16,7 g hvite krystaller, sm.p. 164 - 166°C. Utbytte 56%. 16.7 g white crystals, m.p. 164 - 166°C. Yield 56%.
Produktet ble omkrystallisert fra etylacetat for analyse. The product was recrystallized from ethyl acetate for analysis.
Analyse: Analysis:
Eksempel 2 Example 2
( a) 1- N-( g- etyl- g- metyl- succinimido)- benzen (a) 1-N-(g-ethyl-g-methyl- succinimido)-benzene
27,9 g anilin og 48,0 g a-etyl-a-metyl-ravsyre oppvarmes sammen ved 170°C og holdes ved denne temperatur i 15 minutter. Den resulterende olje opptas i etylacetat, vaskes med vandig NaOH og inndampes i vakuum. Petroleter settes til residuet, og de resulterende krystaller 27.9 g of aniline and 48.0 g of α-ethyl-α-methyl-succinic acid are heated together at 170°C and held at this temperature for 15 minutes. The resulting oil is taken up in ethyl acetate, washed with aqueous NaOH and evaporated in vacuo. Petroleum ether is added to the residue, and the resulting crystals
filtreres for å gi , is filtered to give ,
45,0 g hvite krystaller med et sm.p. 57 - 58°C. Utbytte: 70%. 45.0 g of white crystals with a m.p. 57 - 58°C. Yield: 70%.
( b) 1- N-( g- etyl- g- metyl- succinimido)- 4- klorsulfonyl- benzen 40,0 g 1-N-(a-etyl-a-metyl-succinimido)-benzen settes til 120 ml klorsulfonsyre og oppvarmes under omrøring ved 130°C. (b) 1-N-(g-ethyl-g-methyl-succinimido)-4-chlorosulfonyl-benzene 40.0 g of 1-N-(a-ethyl-a-methyl-succinimido)-benzene is added to 120 ml of chlorosulfonic acid and heated with stirring at 130°C.
Etter å ha vært holdt ved denne temperatur i 5 minutter, helles blandingen i isvann, bunnfalllet filtreres med sugning og opptas i kloroform, noe petroleter tilsettes, og blandingen avkjøles og filtreres After being held at this temperature for 5 minutes, the mixture is poured into ice water, the precipitate is filtered with suction and taken up in chloroform, petroleum ether is added, and the mixture is cooled and filtered
på nytt for å gi again to give
30,0 g hvite krystaller med et sm.p. 115 - 118°C. Utbytt: 51%. 30.0 g of white crystals with a m.p. 115 - 118°C. Yield: 51%.
( c) 1- N-( a- etyl- g- metyl- succinimido)- 4- sulfonamido- benzen (c) 1- N-(a- ethyl- g- methyl- succinimido)- 4- sulfonamido- benzene
Det således erholdte rå sulfonylklorid opptas deretter i kloroform og settes dråpevis under omrøring til konsentrert ammoniakk. Etter oppvarming til 30-40°C under omrøring, inndampes oppløsningen til tørrhet i vakuum, og residuet omkrystalliseres fra etylacetat for å gi farveløse krystaller med et sm.p. 164 - 166°C. The crude sulfonyl chloride thus obtained is then taken up in chloroform and added dropwise with stirring to concentrated ammonia. After heating to 30-40°C with stirring, the solution is evaporated to dryness in vacuo and the residue recrystallized from ethyl acetate to give colorless crystals with a m.p. 164 - 166°C.
Produktet gir ingen smeltepunktnedsettelse med produktet fra eksempel 1. The product does not reduce the melting point with the product from example 1.
(d) (d)
1- N-( a- etyl- a- metyl- succinimido)- 4-( N- etyl- sulfonamido)- benzen 5,0 g av sulfonylkloridet fra (b) ovenfor settes til 5 ml vandig etylamin og oppvarmes under tilbakeløpskjøling 1- N-(a-ethyl-a-methyl- succinimido)- 4-( N- ethyl- sulfonamido)-benzene 5.0 g of the sulfonyl chloride from (b) above is added to 5 ml of aqueous ethylamine and heated under reflux
i 1/2 time. Bunnfallet filtreres med.sugning. Re-r siduet oppløses i etylacetat og inndampes til tørr-het. Residuet, en klar olje, utgnis med eter og filtreres for å gi 3,2 g hvite krystaller som smelter.ved 122 - 128°C. Utbytte: 62%. for 1/2 hour. The precipitate is filtered with suction. The residue is dissolved in ethyl acetate and evaporated to dryness. The residue, a clear oil, is triturated with ether and filtered to give 3.2 g of white crystals melting at 122-128°C. Yield: 62%.
Etter omkrystallisering fra alkohol får man hvite krystaller som smelter ved 133-134°C. After recrystallization from alcohol, white crystals are obtained which melt at 133-134°C.
Analyse: Analysis:
( e) 1- N-( a- etyl- a- metyl- succinimido)- 4-( N- a- hydroksyetyl)-sulfonamido- benzen (e) 1- N-( a- ethyl- a- methyl- succinimido)- 4-( N- a- hydroxyethyl)- sulfonamido- benzene
5,0 g av produktet fra (b) ovenfor oppløses i 20 ml kloroform, og Dissolve 5.0 g of the product from (b) above in 20 ml of chloroform, and
1,94 g etanolamin i 1.94 g of ethanolamine i
20 ml kloroform tilsettes under omrøring og oppvarmes under tilbakeløpskjøling i 1 time. En olje utfelles, noe vann tilsettes, og kloroformlaget adskilles og inndampes. Residuet oppløses i etylacetat, vaskes med vann og inndampes. Eter settes til residuet som utgnis godt og filtreres med sugning for å gi: 3,5 g hvite krystaller som smelter ved 105 - 110°C. 20 ml of chloroform are added with stirring and heated under reflux for 1 hour. An oil precipitates, some water is added, and the chloroform layer is separated and evaporated. The residue is dissolved in ethyl acetate, washed with water and evaporated. Ether is added to the residue which is triturated well and filtered with suction to give: 3.5 g of white crystals melting at 105 - 110°C.
Utbytte: 64%. Yield: 64%.
Etter omkrystallisering fra etylacetat/petroleter får man hvite krystaller som smelter ved 110 - 112°C. After recrystallization from ethyl acetate/petroleum ether, white crystals are obtained which melt at 110 - 112°C.
Analyse: Analysis:
( f) 1- N-( a- etyl- a- metyl- succinimido)- 4-( N- metyl)-sulfanilamido- benzen 5,0 g av produktet fra (b) ovenfor oppløses i 100 ml kloroform, og 15 ml vandig metylamin tilsettes under omrøring ved 35°C. (f) 1-N-(a-ethyl-a-methyl-succinimido)-4-(N-methyl)-sulfanilamido-benzene Dissolve 5.0 g of the product from (b) above in 100 ml of chloroform, and 15 ml aqueous methylamine is added with stirring at 35°C.
Etter omrøring i ytterligere 15 minutter vaskes produktet med kloroform og vann og inndampes i vakuum. Residuet utgnis godt med eter, og krystallene inn- After stirring for a further 15 minutes, the product is washed with chloroform and water and evaporated in vacuo. The residue is rubbed well with ether, and the crystals in
dampes med sugning for å gi steamed with suction to give
3,5 g hvite krystaller med ét sm.p. 122 - 125°C. 3.5 g of white crystals with one m.p. 122 - 125°C.
Utbytte: 71%. Yield: 71%.
Analyse: Analysis:
Eksempel 3 Example 3
N-( g- etyl- a- metyl- hemisuccinyl)- anilin N-(g-ethyl-a-methyl-hemisuccinyl)-aniline
9,3 g anilin oppløses i 9.3 g of aniline are dissolved in
50 ml eter, og 50 ml ether, and
14,2 g a-etyl-a-metyl-ravsyreanhydrid i 14.2 g of α-ethyl-α-methyl-succinic anhydride i
50 ml eter tilsettes. 50 ml of ether is added.
Etter tilsetning av disse bestanddeler, blir opp-løsningen varm og et hvitt bunnfall utskilles. After the addition of these ingredients, the solution becomes warm and a white precipitate separates.
Etter f iltrering med sugning får man After filtering with suction, you get
18,7 g hvite krystaller med sm.p. 160 - 163°C. Etter omkrystallisering fra etylacetat/petroleter får man hvite krystaller med sm.p. 169 - 170°C. 18.7 g of white crystals with m.p. 160 - 163°C. After recrystallization from ethyl acetate/petroleum ether, white crystals with m.p. 169 - 170°C.
Analyse: Analysis:
g- metyl- a- etyl- N- fienylsuccinimid g- methyl- a- ethyl- N- fienyl succinimide
2 g N-(a-etyl-a-metyl-hemisuccinyl)-anilin oppvarmes i 1 time til 180 - 200°C. Efter omsetningen opptas råproduktet i etylacetat. Etylacetatoppløsningen vaskes med fortynnet natronlut og med vann, tørres over natriumsulfat og inndampes. Etylacetatresiduet opp-løses på ny i etylacetat og tilsettes petroleter. Succinimidet utfelles. 2 g of N-(α-ethyl-α-methyl-hemisuccinyl)-aniline is heated for 1 hour to 180 - 200°C. After the reaction, the crude product is taken up in ethyl acetate. The ethyl acetate solution is washed with dilute caustic soda and with water, dried over sodium sulfate and evaporated. The ethyl acetate residue is dissolved again in ethyl acetate and petroleum ether is added. The succinimide is precipitated.
Utbytte: 0,5 g. Yield: 0.5 g.
Forbindelsen er efter smeltepunkt, blandingssmelte-punkt og IR-spektrum identisk med 1-N-(a-etyl-a-metyl-succinimido) -benzen fremstilt ifølge eksempel 2a og omdannes i p-sulfonamido-derivatet som beskrevet i eksempel 2. The compound is in terms of melting point, mixture melting point and IR spectrum identical to 1-N-(α-ethyl-α-methyl-succinimido)-benzene prepared according to example 2a and is converted into the p-sulfonamido derivative as described in example 2.
Ekempel 4 Example 4
N-( g- etyl- g- metyl- hemisuccinyl)- 4- sulfonamido- anilin N-(g-ethyl-g-methyl-hemisuccinyl)-4- sulfonamido-aniline
8,6 g sulfanilamid og 8.6 g of sulfanilamide and
7.1 g g<->etyl-g<->metyl-ravsyreanhydrid oppvarmes sammen ved 100°C og oppløses deretter i etylacetat og NaHCO^-NaHCO^-oppløsningen ansyres med HCl, og bunnfallet filtreres med sugning og tørres. Man får 7.1 g of g<->ethyl-g<->methyl-succinic anhydride are heated together at 100°C and then dissolved in ethyl acetate and the NaHCO^-NaHCO^ solution is acidified with HCl, and the precipitate is filtered with suction and dried. You get
9.2 g hvite krystaller med sm.p. 165 - 168°C, som etter omkrystallisering fra etylacetat/petroleter gir 7,5 g hvite krystaller med sm.p. 173 - 174°C. 9.2 g of white crystals with m.p. 165 - 168°C, which after recrystallization from ethyl acetate/petroleum ether gives 7.5 g of white crystals with m.p. 173 - 174°C.
Analyse: Analysis:
1- N-( a- etyl- g- metyl- succinimido)- 4- sulfonamido- benzen 2 g N-(g<->metyl-g<->etyl-hemisuccinyl)-4-sulfonamido-anilin holdes i 1 time ved 180 - 200°C. Efter avkjøling oppløses råproduktet i etylacetat og filtreres. Den klare etylacetatoppløsning inndampes derefter til ca. halvt volum og avkjøles til 0 - 5°C. Der-ved utkrystalliseres 1- N-(a- ethyl- g- methyl- succinimido)- 4- sulfonamido- benzene 2 g N-(g<->methyl-g<->ethyl-hemisuccinyl)-4-sulfonamido-aniline kept for 1 hour at 180 - 200°C. After cooling, the crude product is dissolved in ethyl acetate and filtered. The clear ethyl acetate solution is then evaporated to approx. half volume and cool to 0 - 5°C. There-wood crystallizes
1,3 g succinimid. 1.3 g of succinimide.
Forbindelsen er efter smeltepunkt, blandingssmelte-punkt, tynnskiktkromatogram og IR-spektrum identisk med 1-N-(g<->etyl-g<->metyl-succinimido)-4-sulfonamidobenzen fremstilt i henhold til eksempel 1 og 2c. According to melting point, mixture melting point, thin layer chromatogram and IR spectrum, the compound is identical to 1-N-(g<->ethyl-g<->methyl-succinimido)-4-sulfonamidobenzene prepared according to examples 1 and 2c.
Eksempel 5 Example 5
1- N-( g, g- dimetyl- succinimido)- 4- sulfonamido- benzen 17,2 g sulfanilamid og 1- N-( g, g- dimethyl- succinimido)- 4- sulfonamido- benzene 17.2 g of sulfanilamide and
14,6 g <g>,<g->dimetyl-ravsyreanhydrid oppvarmes sammen i 30 14.6 g <g>,<g->dimethyl succinic anhydride are heated together for 30
minutter ved 180°C. Etter avkjøling opptas oljen med dioksam, eter tilsettes og det hele avkjøles og filtreres med sugning for å gi minutes at 180°C. After cooling, the oil is taken up with dioxam, ether is added and the whole is cooled and filtered with suction to give
20,4 g hvite krystaller med sm.p. 213 - 215°C, utbytte 72% 20.4 g of white crystals with m.p. 213 - 215°C, yield 72%
etter omkrystallisering fra dimetylformamid/eter. after recrystallization from dimethylformamide/ether.
Analyse: Analysis:
Eksempel 6 Example 6
1- N-( a, g- dietyl- succinimido)- 4- sulfonamido- benzen 17,2 g sulfanilamid og 1- N-(a, g- diethyl- succinimido)- 4- sulfonamido- benzene 17.2 g of sulfanilamide and
17,4 g <g>,<g->dimetyl-ravsyreanhydrid oppvarmes sammen i 20 minutter ved 170°C. Etter avkjøling opptas oljen med etylacetat, avkjøles og filtreres med sugning. Man får 17.4 g <g>,<g->dimethyl succinic anhydride are heated together for 20 minutes at 170°C. After cooling, the oil is taken up with ethyl acetate, cooled and filtered with suction. You get
o o
23,4 g av et lysebrunt produkt med sm.p. 125 - 132 C, 23.4 g of a light brown product with m.p. 125 - 132 C,
utbytte 75%, som etter omkrystallisering fra etylacetat/petroleter gir hvite krystaller med sm.p. yield 75%, which after recrystallization from ethyl acetate/petroleum ether gives white crystals with m.p.
129 - 131°C. 129 - 131°C.
Analyse: Analysis:
Eksempel 7 Example 7
1-( g- metyl- succinimido)- 4- sulfonamido- benzen 1-( g- methyl- succinimido)- 4- sulfonamido- benzene
6,6 g metylravsyre og 6.6 g methylsuccinic acid and
8,6 g sulfanilamid oppvarmes sammen ved 180-190°C og holdes ved denne temperatur i 15 minutter. Efter avkjøling tilsettes etylacetat, og det resulterende bunnfall filtreres med sugning for å gi- 8.6 g of sulfanilamide are heated together at 180-190°C and held at this temperature for 15 minutes. After cooling, ethyl acetate is added, and the resulting precipitate is filtered with suction to give
10,2 g hvite krystaller med sm.p. 237-239°C, som efter omkrystallisering fra aceton gir hvite krystaller med sm.p. 238-240°C. 10.2 g of white crystals with m.p. 237-239°C, which after recrystallization from acetone gives white crystals with m.p. 238-240°C.
Analyse: Analysis:
Eksempal 8 Example 8
1-( g- etyl- succinimido)- 4- sulfonamidobenzen 1-(g-ethyl-succinimido)-4- sulfonamidobenzene
4,9 g etylravsyre og 4.9 g ethyl succinic acid and
5,8 g sulfanilamid oppvarmes sammen med 170-180°C. Etylacetat 5.8 g of sulfanilamide are heated together with 170-180°C. Ethyl acetate
settes derefter til den rødbrune oppløsning, og det is then added to the reddish-brown solution, and that
utfelte produkt filtreres ved sugning. precipitated product is filtered by suction.
8,2 g brune krystaller erholdes, og efter omkrystallisering fra petroleter, får man hvite krystaller med sm.p. 199-200°C. 8.2 g of brown crystals are obtained, and after recrystallization from petroleum ether, white crystals with m.p. 199-200°C.
Analyse; Analysis;
Eksempel 9 Example 9
1- ( a- n- butyl- succinimid6)-_ 4- sul f onamidobenzen 1- (a-n-butyl-succinimide6)-_ 4- sulfonamidobenzene
3,5 g butylravsyre og 3.5 g of butyl succinic acid and
3,5 g sulfanilamid oppvarmes sammen ved 180°C og holdes i 20 3.5 g of sulfanilamide are heated together at 180°C and kept for 20
minutter ved denne temperatur. Efter avkjøling tilsettes etylacetat, og efter henstand natten over, filtreres det resulterende bunnfall ved sugning for minutes at this temperature. After cooling, ethyl acetate is added, and after standing overnight, the resulting precipitate is filtered by suction for
å gi to give
4,0 g beige krystaller, fra hvilke man efter omkrystallisering 4.0 g of beige crystals, from which one recrystallizes
fra etylacetat får hvite flak med sm.p. 203-205°C. from ethyl acetate gives white flakes with m.p. 203-205°C.
Eksempel 10 Example 10
1- ( a- metyl- fB- n- butyl- succinimido) - 4- sulfonamidobenzen 2,0 g g<->metyl-6-n-butyl-ravsyre og 1-(a-methyl-fB-n-butyl-succinimido)-4- sulfonamidobenzene 2.0 g g<->methyl-6-n-butyl-succinic acid and
2,0 g sulfanilamid oppvarmes sammen ved 180°C og holdes ved denne temperatur i 15 minutter. Etylacetat tilsettes efter avkjøling. Det resulterende bunnfall filtreres 2.0 g of sulfanilamide are heated together at 180°C and held at this temperature for 15 minutes. Ethyl acetate is added after cooling. The resulting precipitate is filtered
ved sugning, og man får 1,5 g lysebrune krystaller som efter omkrystallisering fra alkohol gir hvite krystaller med sm.p. 190-192°C. by suction, and 1.5 g of light brown crystals are obtained which, after recrystallization from alcohol, give white crystals with m.p. 190-192°C.
Analyse; Analysis;
Eksempel 11 Example 11
1-( g- metyl- B- n- propyl- succinimido)- 4- sulfonamidobenzen 2,0 g a-B-propylravsyre og 1-( g- methyl- B- n- propyl- succinimido)- 4- sulfonamidobenzene 2.0 g a-B-propylsuccinic acid and
2,0 g sulfanilamid oppvarmes sammen ved 180°C og holdes ved 2.0 g of sulfanilamide are heated together at 180°C and maintained
denne temperatur i 15 minutter. Efter at tempera-turen er sunket til 80°C, tilsettes etylacetat, hvorved et brunt produkt utfelles. Det hele opp-løses i varm etylacetat. Etylacetatoppløsningen ekstraheres med 2N HCl og IN NaHC03, tørres og inndampes for å gi this temperature for 15 minutes. After the temperature has dropped to 80°C, ethyl acetate is added, whereby a brown product is precipitated. The whole is dissolved in hot ethyl acetate. The ethyl acetate solution is extracted with 2N HCl and 1N NaHCO 3 , dried and evaporated to give
1,5 g av et lysbrunt, krystallinsk produkt som oppløses i etylacetat, filtreres over trekull og avkjøles, og det resulterende bunnfall filtreres ved sugning. Man 1.5 g of a light brown crystalline product which is dissolved in ethyl acetate, filtered over charcoal and cooled, and the resulting precipitate is filtered with suction. Mon
får sheep
0,5 g hvite krystaller med et sm.p. 182-188°C, som efter omkrystallisering for analyse gir hvite krystaller med sm.p..190-192°C. 0.5 g of white crystals with a m.p. 182-188°C, which after recrystallization for analysis gives white crystals with m.p. 190-192°C.
Analyse: Analysis:
Eksempel 12 Example 12
1- N-( a- etyl- g- metylsuccinimido)- 4- sulfonamidobenzen (a) 1- N-( q- etyl- a- metylsuccinimido)- 4- nitrobenzen p-Nitroanilin (13,8g) og a-metyl-a-etyl-ravsyre (16,Og) oppvarmes sammen i en kolbe ved 170-180°C i 20 minutter. Blandingen opptas derefter med etylacetat, ekstraheres med HCl og NHCO^, vaskes med vann og konsentreres. Residuet omkrystalliseres fra etylacetat/ 1- N-( a- ethyl- g- methylsuccinimido)- 4- sulfonamidobenzene (a) 1- N-( q- ethyl- a- methylsuccinimido)- 4- nitrobenzene p-Nitroaniline (13.8g) and a-methyl- α-Ethyl succinic acid (16.Og) is heated together in a flask at 170-180°C for 20 minutes. The mixture is then taken up with ethyl acetate, extracted with HCl and NHCO 3 , washed with water and concentrated. The residue is recrystallized from ethyl acetate/
petroleter for å gi petroleum ether to give
11,5 g produkt med smeltepunkt 125-127°C. 11.5 g of product with a melting point of 125-127°C.
Analyse: Analysis:
( b) 1- N- a- etyl- a- metylsuccinimido)- 4- aminobenzen Produktet fra trinn (a) (6,55g) oppløses i iseddik (100 ml) og hydrogeneres under anvendelse av platinaoksyd som katalysator inntil den teoretiske opptagelse av hydrogen er nådd. Blandingen filtreres derefter og inndampes til tørrhet, og residuet blandes med vann. Det uoppløselige residum vaskes med mer vann (b) 1-N-a-ethyl-a-methylsuccinimido)-4-aminobenzene The product from step (a) (6.55g) is dissolved in glacial acetic acid (100 ml) and hydrogenated using platinum oxide as catalyst until the theoretical uptake of hydrogen has been reached. The mixture is then filtered and evaporated to dryness, and the residue is mixed with water. The insoluble residue is washed with more water
og tørres for å gi et råprodukt som efter omkrystallisering fra etylacetat/petroleter gir 5,5 g med smeltepunkt 132-135°C. and dried to give a crude product which, after recrystallization from ethyl acetate/petroleum ether, gives 5.5 g with a melting point of 132-135°C.
Analyse: Analysis:
(c) 1- N-( g- etyl- g- metylsuccinimido)- 4- sulfonamidobenzen Produktet fra trinn (b) (5,5g) oppløses i 2N HCl (100 ml) ved 0°C og en blanding av NaN02 (l,7g) i vann (20 ml) tilsettes langsont dråpevis. Den således dannede diazoniumoppløsning settes dråpevis ved 20°C til en blanding av iseddik (40 ml) metted med SO2 og en oppløsning av Cugl^ (3,3g) i vann (20 ml) under om-røring og kontinuerlig innføring av SOj. Nitrogen utvikles, og et brunt produkt utfelles. Dette produkt frafiltreres under sugning, oppløses i kloroform (50 ml), og konsentrert ammoniakk (50 ml) tilsettes dråpevis ved 20°C. Denne blanding tilbake-løpsbehandles i 15 minutter og konsentreres derefter i vakuum. Residuet oppløses i etylacetat, vaskes med vann, og acetylacetatlaget tørres og inndampes for å (c) 1- N-( g- ethyl- g- methylsuccinimido)- 4- sulfonamidobenzene The product from step (b) (5.5g) is dissolved in 2N HCl (100 ml) at 0°C and a mixture of NaN02 (l .7g) in water (20 ml) is added dropwise over time. The diazonium solution thus formed is added dropwise at 20°C to a mixture of glacial acetic acid (40 ml) saturated with SO2 and a solution of Cugl^ (3.3g) in water (20 ml) with stirring and continuous introduction of SOj. Nitrogen is evolved, and a brown product is precipitated. This product is filtered off with suction, dissolved in chloroform (50 ml), and concentrated ammonia (50 ml) is added dropwise at 20°C. This mixture is refluxed for 15 minutes and then concentrated in vacuo. The residue is dissolved in ethyl acetate, washed with water, and the acetyl acetate layer is dried and evaporated to
gi give
0,3 g råprodukt. Omkrystallisering fra etylacetat/petroleter gir hvite krystaller med sm.p. 164-166°C (ingen senkning av smeltepunktet for.en prøve av produktet fra eksempel 1). 0.3 g raw product. Recrystallization from ethyl acetate/petroleum ether gives white crystals with m.p. 164-166°C (no lowering of the melting point for a sample of the product from Example 1).
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI841048A FI68027C (en) | 1984-03-15 | 1984-03-15 | ANORDNING FOER TOEMNING AV TRANSPORT- OCH / ELLER LAGERBEHAOLLARE |
Publications (3)
Publication Number | Publication Date |
---|---|
NO850974L NO850974L (en) | 1985-09-16 |
NO165229B true NO165229B (en) | 1990-10-08 |
NO165229C NO165229C (en) | 1991-01-16 |
Family
ID=8518742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO850974A NO165229C (en) | 1984-03-15 | 1985-03-12 | DEVICE FOR EMPTYING A FLEXIBLE TRANSPORT CONTAINER. |
Country Status (5)
Country | Link |
---|---|
DK (1) | DK112585A (en) |
FI (1) | FI68027C (en) |
GB (1) | GB2155913B (en) |
NO (1) | NO165229C (en) |
SE (1) | SE455495B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2593068A1 (en) * | 1986-01-21 | 1987-07-24 | Lebiedinsky Georges | Device for fastening a canula onto a container with a flexible wall |
US4722457A (en) * | 1986-09-05 | 1988-02-02 | Fibre Glass-Evercoat Company, Inc. | Dispensing device |
GB2445558A (en) * | 2007-01-10 | 2008-07-16 | Jagdish Pal Singh | Bulk bag with side outlet |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB241813A (en) * | 1925-04-29 | 1925-10-29 | William Mark Moore | An improved construction of discharging means for benzine and like tins |
GB634506A (en) * | 1947-02-28 | 1950-03-22 | Ile Bemex Soc Civ | Combined tin-opener and pouring device |
-
1984
- 1984-03-15 FI FI841048A patent/FI68027C/en not_active IP Right Cessation
-
1985
- 1985-03-12 NO NO850974A patent/NO165229C/en unknown
- 1985-03-12 SE SE8501227A patent/SE455495B/en not_active IP Right Cessation
- 1985-03-12 DK DK112585A patent/DK112585A/en not_active Application Discontinuation
- 1985-03-15 GB GB08506845A patent/GB2155913B/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
SE8501227D0 (en) | 1985-03-12 |
GB8506845D0 (en) | 1985-04-17 |
FI68027C (en) | 1985-07-10 |
SE8501227L (en) | 1985-09-16 |
NO165229C (en) | 1991-01-16 |
NO850974L (en) | 1985-09-16 |
SE455495B (en) | 1988-07-18 |
GB2155913A (en) | 1985-10-02 |
FI68027B (en) | 1985-03-29 |
GB2155913B (en) | 1987-09-30 |
FI841048A0 (en) | 1984-03-15 |
DK112585D0 (en) | 1985-03-12 |
DK112585A (en) | 1985-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK159777B (en) | N-ALKYL NORSCOPINES AND PROCEDURES FOR PREPARING THEM AND THEIR USE AS INTERMEDIATES | |
MXPA01012237A (en) | Method for the production of thiazolidin. | |
DK159680B (en) | CYCLIC IMIDES USED FOR THE PREPARATION OF CYCLIC AMINO ACIDS | |
IE43531B1 (en) | 1-sulphonyl-2-(amino or acylamino)-benzimidazoles | |
SU548207A3 (en) | The method of obtaining derivatives of 2-arylamino-2-imidazoline or their salts | |
US4328155A (en) | Meta-sulfonamido-benzamides | |
Wuest et al. | Some Derivatives of 3-Pyridol with Parasympathomimetic Properties1 | |
DK158658B (en) | METHOD OF ANALOGUE FOR THE PREPARATION OF 9-AMINOAL COOLFluorens OR PHARMACEUTICAL ACCEPTABLE SALTS THEREOF | |
FI97294B (en) | Process for the preparation of bis (3,5-dioxpiperazinyl) alkanes or alkenes | |
NO165229B (en) | DEVICE FOR EMPTYING A FLEXIBLE TRANSPORT CONTAINER. | |
US4078086A (en) | Anthraquinone-bis-amidines and process for preparing them | |
US3350403A (en) | Nu-phenyl amides of 4-phenyl-4-hydroxypiperidino alkyl acids | |
Gautun et al. | Synthesis of bis ((-alkylaminobenzylidene) hydrazines and their transformation into 4-alky-4H-1, 2, 4-triazoles | |
US3576808A (en) | N-4-phenyl-1-piperazinylalkyl-5-phenyl-oxazolidinones | |
US4271300A (en) | Method for producing 6,7-dimethoxy-4-amino-2-[4-(2-furoyl)-1-piperazinyl] qu | |
HU181580B (en) | Process for preparing 1-benzoxepin-5/2h/-one derivatives | |
US3936459A (en) | 1',4'-Dihydro-1-methyl-spiro [piperidine and pyrrolidine-2,3'(2'H)quinoline]-2'-one compounds | |
NO135092B (en) | ||
DE69207597T2 (en) | LIPOXYGENASE INHIBITING TETRAHYDROBENZAZEPINE DERIVATIVES | |
US4703055A (en) | Benzamides and therapeutic use thereof | |
HU196794B (en) | Process for producing new benzamide derivatives | |
Takei et al. | The Preparation of Iminosulfonic Acid Derivatives by Means of Sulfinamides and N-Bromosuccinimide | |
FI65426C (en) | ANALOGIFICATION OF THE NUTRITIONAL PHARMACOLOGICAL VERIFICATION OF N- (2-MORPHOLINOETHYL) BENZENIDE | |
US2721196A (en) | Bicyclic lactams | |
US3378592A (en) | Process for the production of 3, 4-dihydroxybenzyloxyaminehydrobromide |